This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

'Stable' is indefinite, US judge rules in win for Nexus Pharmaceuticals

( May 9, 2025, 18:18 GMT | Official Statement) -- MLex Summary: Use of the term "stable" in all four claims of Ingenus Pharmaceuticals’ US Patent No. 10,993,952 renders the patent invalid as indefinite because it fails to inform a person of skill in the art, or POSA, with reasonable certainty the “test or conditions a similar invention could be said to infringe, US Judge Mary M. Rowland of the Northern District of Illinois ruled. The '952 patent covers an injectable formulation of the anti-cancer treatment cyclophosphamide.See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections